Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Breast Cancer

  Free Subscription


15.07.2019

1 Am J Surg Pathol
1 Ann Oncol
1 Ann Surg
4 Ann Surg Oncol
2 BMC Cancer
1 Br J Cancer
2 Breast Cancer
2 Breast Cancer Res
7 Breast Cancer Res Treat
6 Breast J
2 Cancer
2 Cancer Chemother Pharmacol
1 Cancer Epidemiol Biomarkers Prev
2 Cancer Res
5 Clin Breast Cancer
1 Clin Cancer Res
1 Eur J Cancer
1 Eur J Surg Oncol
1 Eur Radiol
1 Gene
1 Int J Radiat Oncol Biol Phys
1 J Clin Invest
1 J Natl Cancer Inst
1 J Pathol
1 J Surg Oncol
1 Lancet
3 Nat Rev Clin Oncol
1 Oncogene
6 PLoS One
3 Radiology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Surg Pathol

  1. VAN ES SC, van der Vegt B, Bensch F, Gerritse S, et al
    Decalcification of Breast Cancer Bone Metastases With EDTA Does Not Affect ER, PR, and HER2 Results.
    Am J Surg Pathol. 2019 Jul 5. doi: 10.1097/PAS.0000000000001321.
    PubMed     Text format     Abstract available


    Ann Oncol

  2. LOI S
    The ESMO clinical practise guidelines for early breast cancer: diagnosis, treatment and follow-up: on the winding road to personalized medicine.
    Ann Oncol. 2019 Jul 9. pii: 5530161. doi: 10.1093.
    PubMed     Text format    


    Ann Surg

  3. DUPONT E, Tsangaris T, Garcia-Cantu C, Howard-McNatt M, et al
    Resection of Cavity Shave Margins in Stage 0-III Breast Cancer Patients Undergoing Breast Conserving Surgery: A Prospective Multicenter Randomized Controlled Trial.
    Ann Surg. 2019 Jul 8. doi: 10.1097/SLA.0000000000003449.
    PubMed     Text format     Abstract available


    Ann Surg Oncol

  4. ALVARADO MD, Mittendorf EA, Teshome M, Thompson AM, et al
    SentimagIC: A Non-inferiority Trial Comparing Superparamagnetic Iron Oxide Versus Technetium-99m and Blue Dye in the Detection of Axillary Sentinel Nodes in Patients with Early-Stage Breast Cancer.
    Ann Surg Oncol. 2019 Jul 11. pii: 10.1245/s10434-019-07577.
    PubMed     Text format     Abstract available

  5. WHITWORTH P, Schonholz S, Phillips R, Robertson Y, et al
    Minimally Invasive Intact Excision of High-Risk Breast Lesions and Small Breast Cancers: The Intact Percutaneous Excision (IPEX) Registry.
    Ann Surg Oncol. 2019;26:954-960.
    PubMed     Text format     Abstract available

  6. DOWNS-CANNER S, Zabor EC, Wind T, Cobovic A, et al
    Radiation Therapy After Breast-Conserving Surgery in Women 70 Years of Age and Older: How Wisely Do We Choose?
    Ann Surg Oncol. 2019;26:969-975.
    PubMed     Text format     Abstract available

  7. YAO K
    Intact Excision of Breast Lesions Using BLES: Is There a Clinical Indication Yet?
    Ann Surg Oncol. 2019;26:933-935.
    PubMed     Text format    


    BMC Cancer

  8. LIM SM, Han Y, Kim SI, Park HS, et al
    Utilization of bioelectrical impedance analysis for detection of lymphedema in breast Cancer survivors: a prospective cross sectional study.
    BMC Cancer. 2019;19:669.
    PubMed     Text format     Abstract available

  9. MARTIN-PARDILLOS A, Valls Chiva A, Bande Vargas G, Hurtado Blanco P, et al
    The role of clonal communication and heterogeneity in breast cancer.
    BMC Cancer. 2019;19:666.
    PubMed     Text format     Abstract available


    Br J Cancer

  10. LEE DW, Ryu HS, Jin MS, Lee KH, et al
    Immune recurrence score using 7 immunoregulatory protein expressions can predict recurrence in stage I-III breast cancer patients.
    Br J Cancer. 2019 Jul 11. pii: 10.1038/s41416-019-0511.
    PubMed     Text format     Abstract available


    Breast Cancer

  11. IIOKA Y, Iwata T, Yamauchi H
    Symptoms and QOL in breast cancer patients receiving hormone therapy in Japan.
    Breast Cancer. 2019 Jul 11. pii: 10.1007/s12282-019-00993.
    PubMed     Text format     Abstract available

  12. MOON G, Noh H, Cho IJ, Lee JI, et al
    Prediction of late recurrence in patients with breast cancer: elevated neutrophil to lymphocyte ratio (NLR) at 5 years after diagnosis and late recurrence.
    Breast Cancer. 2019 Jul 6. pii: 10.1007/s12282-019-00994.
    PubMed     Text format     Abstract available


    Breast Cancer Res

  13. PALOMERAS S, Diaz-Lagares A, Vinas G, Setien F, et al
    Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer.
    Breast Cancer Res. 2019;21:79.
    PubMed     Text format     Abstract available

  14. XING Y, Lin NU, Maurer MA, Chen H, et al
    Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.
    Breast Cancer Res. 2019;21:78.
    PubMed     Text format     Abstract available


    Breast Cancer Res Treat

  15. ISNALDI E, Ferraioli D, Ferrando L, Brohee S, et al
    Correction to: Schlafen-11 expression is associated with immune signatures and basal-like phenotype in breast cancer.
    Breast Cancer Res Treat. 2019 Jul 12. pii: 10.1007/s10549-019-05348.
    PubMed     Text format     Abstract available

  16. ALEIXO GFP, Williams GR, Nyrop KA, Muss HB, et al
    Muscle composition and outcomes in patients with breast cancer: meta-analysis and systematic review.
    Breast Cancer Res Treat. 2019 Jul 11. pii: 10.1007/s10549-019-05352.
    PubMed     Text format     Abstract available

  17. JOHNSON HM, Irish W, Muzaffar M, Vohra NA, et al
    Quantifying the relationship between age at diagnosis and breast cancer-specific mortality.
    Breast Cancer Res Treat. 2019 Jul 11. pii: 10.1007/s10549-019-05353.
    PubMed     Text format     Abstract available

  18. MARINO MA, Gucalp A, Leithner D, Keating D, et al
    Mammographic screening in male patients at high risk for breast cancer: is it worth it?
    Breast Cancer Res Treat. 2019 Jul 6. pii: 10.1007/s10549-019-05338.
    PubMed     Text format     Abstract available

  19. MURATA T, Yanagisawa T, Kurihara T, Kaneko M, et al
    Salivary metabolomics with alternative decision tree-based machine learning methods for breast cancer discrimination.
    Breast Cancer Res Treat. 2019 Jul 8. pii: 10.1007/s10549-019-05330.
    PubMed     Text format     Abstract available

  20. JACOT W, Dalenc F, Lopez-Crapez E, Chaltiel L, et al
    PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy.
    Breast Cancer Res Treat. 2019 Jul 11. pii: 10.1007/s10549-019-05349.
    PubMed     Text format     Abstract available

  21. KUROZUMI S, Kaira K, Matsumoto H, Hirakata T, et al
    beta2-Adrenergic receptor expression is associated with biomarkers of tumor immunity and predicts poor prognosis in estrogen receptor-negative breast cancer.
    Breast Cancer Res Treat. 2019 Jul 9. pii: 10.1007/s10549-019-05341.
    PubMed     Text format     Abstract available


    Breast J

  22. ZNIDARIC T, Gugic J, Marinko T, Gojkovic Horvat A, et al
    Breast cancer patients with brain metastases or leptomeningeal disease: 10-year results of a national cohort with validation of prognostic indexes.
    Breast J. 2019 Jul 8. doi: 10.1111/tbj.13433.
    PubMed     Text format     Abstract available

  23. YIP RHL, Yong-Hing CJ, Farinha PMS, Hayes MM, et al
    Isolated intramammary Kikuchi-Fujimoto disease, a mimic of breast cancer.
    Breast J. 2019 Jul 12. doi: 10.1111/tbj.13466.
    PubMed     Text format    

  24. WEI F, Chen W, Lin X
    Efficacy and safety of adjuvant endocrine therapy in premenopausal patients with early-stage hormone receptor-positive breast cancer: A meta-analysis of randomized controlled trials.
    Breast J. 2019 Jul 12. doi: 10.1111/tbj.13465.
    PubMed     Text format    

  25. PHADKE S, Vander Weg M, Itani N, Grogan N, et al
    Breast cancer patient preferences for test result communication.
    Breast J. 2019 Jul 12. doi: 10.1111/tbj.13461.
    PubMed     Text format    

  26. OU D, Cao L, Xu C, Kirova Y, et al
    Upfront brain radiotherapy may improve survival for unfavorable prognostic breast cancer brain metastasis patients with Breast-GPA 0-2.0.
    Breast J. 2019 Jul 8. doi: 10.1111/tbj.13426.
    PubMed     Text format     Abstract available

  27. PATTERSON-LOMBA O, Dalal AA, Ayyagari R, Liu O, et al
    Systematic literature review of clinical trials of endocrine therapies for premenopausal women with metastatic HR+ HER2- breast cancer.
    Breast J. 2019 Jul 9. doi: 10.1111/tbj.13345.
    PubMed     Text format     Abstract available


    Cancer

  28. PRINTZ C
    First person profile: Larry Norton, MD: A world-renowned breast cancer researcher, Dr. Norton has used his passion for music and math to revolutionize oncology.
    Cancer. 2019;125:2525-2527.
    PubMed     Text format    

  29. SCOTT LC, Mobley LR, Kuo TM, Il'yasova D, et al
    Update on triple-negative breast cancer disparities for the United States: A population-based study from the United States Cancer Statistics database, 2010 through 2014.
    Cancer. 2019 Jul 8. doi: 10.1002/cncr.32207.
    PubMed     Text format     Abstract available


    Cancer Chemother Pharmacol

  30. CAO L, Xiang G, Liu F, Xu C, et al
    A high AR:ERalpha or PDEF:ERalpha ratio predicts a sub-optimal response to tamoxifen therapy in ERalpha-positive breast cancer.
    Cancer Chemother Pharmacol. 2019 Jul 11. pii: 10.1007/s00280-019-03891.
    PubMed     Text format     Abstract available

  31. CHEN X, Li C, Ewesuedo R, Yin D, et al
    Correction to: Population pharmacokinetics of PF05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin((R))) in patients with HER2positive metastatic breast cancer.
    Cancer Chemother Pharmacol. 2019 Jul 10. pii: 10.1007/s00280-019-03890.
    PubMed     Text format     Abstract available


    Cancer Epidemiol Biomarkers Prev

  32. BOOMS A, Coetzee GA, Pierce SE
    MCF-7 as a model for functional analysis of breast cancer risk variants.
    Cancer Epidemiol Biomarkers Prev. 2019 Jul 10. pii: 1055-9965.EPI-19-0066.
    PubMed     Text format     Abstract available


    Cancer Res

  33. PRIETO-VILA M, Usuba W, Takahashi RU, Shimomura I, et al
    Single-cell Analysis Reveals a Preexisting Drug-Resistant Subpopulation in the Luminal Breast Cancer Subtype.
    Cancer Res. 2019 Jul 9. pii: 0008-5472.CAN-19-0122.
    PubMed     Text format     Abstract available

  34. HE L, Yuan L, Sun Y, Wang P, et al
    Glucocorticoid receptor signaling activates TEAD4 to promote breast cancer progression.
    Cancer Res. 2019 Jul 9. pii: 0008-5472.CAN-19-0012.
    PubMed     Text format     Abstract available


    Clin Breast Cancer

  35. LEVASSEUR N, Willemsma KA, Li H, Gondara L, et al
    Efficacy of Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in ER-positive Breast Cancer: Results From a Prospective Institutional Database.
    Clin Breast Cancer. 2019 Jun 11. pii: S1526-8209(19)30033.
    PubMed     Text format     Abstract available

  36. BOEHM L, Weisberg T, Linendoll N, Damon AC, et al
    Development of Phase-Specific Breast Cancer Survivorship Care Plans.
    Clin Breast Cancer. 2019 Jun 5. pii: S1526-8209(19)30138.
    PubMed     Text format     Abstract available

  37. LIVINGSTON-ROSANOFF D, Schumacher J, Vande Walle K, Stankowski-Drengler T, et al
    Does Tumor Size Predict Response to Neoadjuvant Chemotherapy in the Modern Era of Biologically Driven Treatment? A Nationwide Study of US Breast Cancer Patients.
    Clin Breast Cancer. 2019 Jun 6. pii: S1526-8209(19)30303.
    PubMed     Text format     Abstract available

  38. DREHER N, Hadeler EK, Hartman SJ, Wong EC, et al
    Fitbit Usage in Patients With Breast Cancer Undergoing Chemotherapy.
    Clin Breast Cancer. 2019 May 25. pii: S1526-8209(19)30229.
    PubMed     Text format     Abstract available

  39. STUEBER TN, Wischnewsky M, Leinert E, Diessner J, et al
    B(2) Prognostic Score: External Validation of a Clinical Decision-making Tool for Metastatic Breast Cancer.
    Clin Breast Cancer. 2019 May 3. pii: S1526-8209(18)30867.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  40. DOWNS B, Mercado-Rodriguez C, Cimino-Mathews A, Chen C, et al
    DNA Methylation Markers for Breast Cancer Detection in the Developing World.
    Clin Cancer Res. 2019 Jul 12. pii: 1078-0432.CCR-18-3277.
    PubMed     Text format     Abstract available


    Eur J Cancer

  41. DI COSIMO S, Triulzi T, Pizzamiglio S, De Cecco L, et al
    The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study.
    Eur J Cancer. 2019;118:1-9.
    PubMed     Text format     Abstract available


    Eur J Surg Oncol

  42. ZACHARIOUDAKIS K, Down S, Bholah Z, Lee S, et al
    Is the future magnetic? Magseed localisation for non palpable breast cancer. A multi-centre non randomised control study.
    Eur J Surg Oncol. 2019 Jun 26. pii: S0748-7983(19)30529.
    PubMed     Text format     Abstract available


    Eur Radiol

  43. BLANKS RG, Given-Wilson RM, Cohen SL, Patnick J, et al
    Correction to: An analysis of 11.3 million screening tests examining the association between recall and cancer detection rates in the English NHS breast cancer screening programme.
    Eur Radiol. 2019 Jul 5. pii: 10.1007/s00330-019-06307.
    PubMed     Text format     Abstract available


    Gene

  44. RAMEZANI S, Sharafshah A, Mirzanejad L, Hadavi M, et al
    Association of PARP1 rs4653734, rs907187 and rs1136410 variants with breast cancer risk among Iranian women.
    Gene. 2019;712:143954.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  45. HUANG TT, Ching-Hsuan Chen A, Lu TP, Lei L, et al
    Clinical-Genomic Models of Node-Positive Breast Cancer: Training, Testing, and Validation.
    Int J Radiat Oncol Biol Phys. 2019 Jul 8. pii: S0360-3016(19)33446.
    PubMed     Text format     Abstract available


    J Clin Invest

  46. PRIMAC I, Maquoi E, Blacher S, Heljasvaara R, et al
    Stromal integrin alpha11 regulates PDGFR-beta signaling and promotes breast cancer progression.
    J Clin Invest. 2019;130.
    PubMed     Text format     Abstract available


    J Natl Cancer Inst

  47. AZAM S, Eriksson M, Sjolander A, Hellgren R, et al
    Mammographic Density Change and Risk of Breast Cancer.
    J Natl Cancer Inst. 2019 Jul 12. pii: 5531652. doi: 10.1093.
    PubMed     Text format     Abstract available


    J Pathol

  48. SEOANE S, Martinez-Ordonez A, Eiro N, Cabezas-Sainz P, et al
    POU1F1 transcription factor promotes breast cancer metastasis via recruitment and polarization of macrophages.
    J Pathol. 2019 Jul 11. doi: 10.1002/path.5324.
    PubMed     Text format     Abstract available


    J Surg Oncol

  49. LEE TC, Reyna C, Shaughnessy E, Lewis JD, et al
    Screening of populations at high risk for breast cancer.
    J Surg Oncol. 2019 Jul 8. doi: 10.1002/jso.25611.
    PubMed     Text format     Abstract available


    Lancet

  50. HURVITZ SA
    Is the duration of adjuvant trastuzumab debate still clinically relevant?
    Lancet. 2019;393:2565-2567.
    PubMed     Text format    


    Nat Rev Clin Oncol

  51. ROMERO D
    Healthier bones and less recurrence with denosumab.
    Nat Rev Clin Oncol. 2019;16:272.
    PubMed     Text format    

  52. SIDAWAY P
    Early PET response predicts complete response.
    Nat Rev Clin Oncol. 2019;16:208.
    PubMed     Text format    

  53. KILLOCK D
    CTCs 'piggyback' off neutrophils.
    Nat Rev Clin Oncol. 2019;16:208.
    PubMed     Text format    


    Oncogene

  54. QIAN JY, Gao J, Sun X, Cao MD, et al
    KIAA1429 acts as an oncogenic factor in breast cancer by regulating CDK1 in an N6-methyladenosine-independent manner.
    Oncogene. 2019 Jul 8. pii: 10.1038/s41388-019-0861.
    PubMed     Text format     Abstract available


    PLoS One

  55. HERR D, Wischnewsky M, Joukhadar R, Chow O, et al
    Does chemotherapy improve survival in patients with nodal positive luminal A breast cancer? A retrospective Multicenter Study.
    PLoS One. 2019;14:e0218434.
    PubMed     Text format     Abstract available

  56. HEQUET D, Huchon C, Soilly AL, Asselain B, et al
    Direct medical and non-medical costs of a one-year care pathway for early operable breast cancer: Results of a French multicenter prospective study.
    PLoS One. 2019;14:e0210917.
    PubMed     Text format     Abstract available

  57. IMRAN M, Al-Wassia R, Alkhayyat SS, Baig M, et al
    Assessment of quality of life (QoL) in breast cancer patients by using EORTC QLQ-C30 and BR-23 questionnaires: A tertiary care center survey in the western region of Saudi Arabia.
    PLoS One. 2019;14:e0219093.
    PubMed     Text format     Abstract available

  58. STUR E, Aristizabal-Pachon AF, Peronni KC, Agostini LP, et al
    Glyphosate-based herbicides at low doses affect canonical pathways in estrogen positive and negative breast cancer cell lines.
    PLoS One. 2019;14:e0219610.
    PubMed     Text format     Abstract available

  59. EKDAHL HJELM T, Matovu A, Mugisha N, Lofgren J, et al
    Breast cancer care in Uganda: A multicenter study on the frequency of breast cancer surgery in relation to the incidence of breast cancer.
    PLoS One. 2019;14:e0219601.
    PubMed     Text format     Abstract available


  60. Retraction: Biomarkers for Presymptomatic Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients.
    PLoS One. 2019;14:e0219887.
    PubMed     Text format    


    Radiology

  61. MANN RM
    Do We Need Optoacoustic Assessment of Hypoxia to Differentiate Molecular Subtypes of Breast Cancer?
    Radiology. 2019 Jul 9:191263. doi: 10.1148/radiol.2019191263.
    PubMed     Text format    

  62. LANG K
    The Coming of Age of Breast Tomosynthesis in Screening.
    Radiology. 2019;291:31-33.
    PubMed     Text format    

  63. SHAFFER K
    Mammographic Parenchymal Analysis: Can We Do Better with Digital Assistance?
    Radiology. 2019 Feb 12:190085. doi: 10.1148/radiol.2019190085.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: